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of RCC-treatment in Finland. METHODS: Health care resource use, medication and 
survival data from 83 patients with metastatic RCC, who had received 1st line inter-
feron-based therapy, were collected from the hospital records of 3 university hospitals. 
A structured form was utilized in the retrospective data collection. Kaplan-Meier 
method was used in survival analysis. RESULTS: Median survival time from diagnosis 
to death was 20.7 months (95%CI 14.9–26.4). All patients had received interferon-A 
(IFN) as the cytokine of choice, the duration of IFN-treatment was 5.6 months 
(median). Patients survived 11.9 months (95%CI 9.2–14.7) after initiation of active 
IFN-treatment. Median survival time after IFN-treatment failure was 3.8 months 
(95%CI 1.38–6.3). There were no signiﬁcant differences in survival times between 
the hospitals. Most of the total treatment costs were due to hospitalization and IFN-
treatment. The average treatment cost per follow-up day was a36 in population level. 
IFN-A caused 89% (median a7170/patient) of all medication costs. Hospitalization 
was responsible for majority of total non-medication costs (78%; median a10,980/
patient). The composition of different costs changed during disease progression. 
During active treatment period, the medication costs comprised the majority (60%) 
of total treatment costs. After the active IFN-treatment was stopped, i.e. during 
 palliative phase, 94% of all costs were non-medication costs. Average cost per 
 treatment day was less during the active treatment than after disease progression. 
CONCLUSIONS: Prolonging progression-free time and keeping patients out of 
 hospital provide desirable outcomes both from humanistic and from economic 
 perspective. New targeted treatments have shown their potential in the treatment of 
RCC. Nevertheless, their economic consequences should be carefully evaluated.
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OBJECTIVES: Febrile neutropenia (FN) is a side effect of chemotherapy, inducing 
signiﬁcant morbidity and mortality. A previous study showed that MASCC score can 
distinguish patients according to their risk of FN-related complications. The objective 
of this study was to assess the predictive value of the MASCC score in identifying 
patient management options following an FN episode. METHODS: Prospective study 
of consecutive patients with a solid tumour and FN. According to the MASCC score 
and the antibiotic treatment, 3 management groups were deﬁned: ambulatory (A  
MASCC  21 and oral antibiotics), hospitalization (H  MASCC a 19 and IV antibiot-
ics) or short hospitalization followed by outpatient management (AH  16 a MASCC 
a 26 and oral antibiotics). Data were collected on demographic, clinical, biological 
and therapeutic characteristics, as well as serious FN complications. Costs were ana-
lyzed from the societal perspective. Resources consumed (hospitalization, drugs, bio-
logical exams, transportations and follow-up) were collected during hospitalization 
and outpatient management. RESULTS: From January 2008 to April 2009, 138 FN 
episodes were registered in 128 patients. Mean age was 53 years and 77 patients were 
women. Thirteen patients received prophylaxis for FN with G-CSF. Twenty-seven 
episodes (20%) were managed at home (A): there was no complication and mean 
treatment cost was 498a o 748. Thirty nine episodes (28%) were treated in hospitaliza-
tion (group H) for a mean of 6.9 days. Nine episodes were treated curatively with G-
CSF. There were 8 complications, including 3 FN-related deaths, leading to a mean 
management cost of 6216a o 3844. The AH group was composed of 72 episodes 
(52%). Secondary prophylaxis by G-CSF concerned 15 episodes (20%). There was no 
complication and no death in this group. Patients were hospitalized for a mean of 4.1 
o 2.2 days, management cost being estimated at 3738a o 2038. CONCLUSIONS: 
MASCC score and type of antibiotic treatment allowed optimal management of 
patient to be determined. Future research would identify factors distinguishing high-
risk patients from the intermediary population.
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OBJECTIVES: To evaluate the medical, non-medical and indirect resources used in a 
group of patients with anemia induced by chemotherapy requiring blood transfusions 
and their associated costs. METHODS: An epidemiological, prospective study was 
conducted in 19 Spanish hospital sites during 2007–2008. 108 patients with anemia 
induced by chemotherapy were included and ﬁnally 32 patients who required blood 
transfusions were analyzed. The consumption of resources was obtained through two 
medical visits: basal and 5 months later. The resources and costs estimated were: (i) 
direct medical: related to blood transfusions; (ii) Indirect: workplace absence for 
patients and carers; (iii) direct non-medical: transportation to the hospital. The time 
horizon used was 5 months. RESULTS: The mean age of patients was: 62.1 o 8.6 
years old; 90.6% were men. Mean basal Hb level was 9.33 o 0.96 g/dl. and years  
from disease diagnostic: 0.50 o 0.96. (i) Direct medical costs: each patient received       
3.7 o 2.6 units of red cell concentrates, the estimated cost was 306.40a. Mean length 
of stay due to transfusions was 318.6 o 280.2 minutes, the mean cost per patient was 
a699.22; (ii) Indirect costs: all patients visited the hospital with a carer; 16.1% of 
patients and 24.1% of carers had an employment, the estimated cost per patient and      
carer was a33.82; (iii) Direct non-medical costs: the means of transport used were car           
(60.7%), taxi (21.4%) and bus/metro (17.9%); being mean cost per patient/carer     
a3.13. The total cost along 5 months, from the social perspective, related to blood             
transfusions in a patient with anemia induced by chemotherapy was a1,042.57/trans-
fusion. CONCLUSIONS: According to the study, blood transfusions in patients with 
anemia induced by chemotherapy involve substantial costs due to consumption of 
medical and non-medical resources.
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OBJECTIVES: The potentially limited generalisability of RCT-based economic analy-
sis may seriously restrict their relevance to policy-making. Therefore, the present study 
aimed to examine the costs of adjuvant treatment in stage III colon cancer based on 
real-world resource use. In addition, we determined the economic burden in the 
Netherlands. METHODS: Real-world data were gathered from the Dutch population-
based Cancer Registry supplemented with data from medical records in 19 hospitals. 
We were able to observe treatment patterns in clinical practice during 2005–2006 
(N  427). From a representative patient sample (N  206), mean costs per patient 
were calculated in regard to the four most common treatment groups. Total costs for 
individual patients were determined by estimating resource use and unit costs of all 
relevant cost components. All costs were reported in euro 2007. RESULTS: Four 
percent of the patients received ﬂuorouracil plus leucovorin (5FU/LV), 24% received 
capecitabine, 35% received 5FU/LV plus oxaliplatin and 37% received capecitabine 
plus oxaliplatin. Mean costs per patient amounted to a8,968, a9,901, a32,593 and 
a23,593 respectively. We found a substantial cost variation in the total costs obtained 
for individual patients as well as in each individual cost component. Inpatient hospital 
days, daycare treatments, outpatient visits and chemotherapy (leucovorin, capecitab-
ine and oxaliplatin) were the most important cost drivers. Extrapolating the mean 
treatment cost per treatment group to all patients treated in 2005 and 2006 (n  2248) 
resulted in an economic burden of a26.1 million per year. CONCLUSIONS: Our 
results suggest a trend towards oxaliplatin plus either 5FU/LV or capecitabine as the 
preferred treatment for stage III colon cancer which is in line with national guidelines. 
Furthermore, a trend towards capecitabine is observed. This can be encouraged by 
lower treatment costs for capecitabine plus oxaliplatin over 5FU/LV plus oxaliplatin 
which may in part relieve the economic burden of stage III colon cancer in the 
future.
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OBJECTIVES: To better understand the economic implications of breast cancer on 
Korean society, it is important to quantify the costs of interventions during the late 
stage of breast cancer. This study was designed to examine the treatment costs in 
patients with metastatic breast cancer based on the clinical practice guidelines in breast 
cancer from Korea Breast Cancer Society. METHODS: To estimate the treatment costs 
consisting of drug and administration, we identiﬁed the preferred regimens for meta-
static breast cancer from the Korean clinical practice guidelines in breast cancer; 
‘Preferred single agents’, ‘Preferred agents with Bevacizumab’, ‘Preferred Chemother-
apy Combination’, ‘Preferred ﬁrst-line agents with trastuzumab for HER2-positive 
disease’ and ‘Preferred agents for trastuzumab-exposed HER2-positive disease’. Mean 
body surface area and weight of female adults in Korea were obtained from the Korea 
National Health and Nutritional Examination Survey (KNHANES). Costs of each 
agent and the administration costs were drawn from Korean pharmaceutical pricing 
lists, and the published chemotherapeutic administration reference from Health Insur-
ance Review & Assessment Service, respectively. Shares of metastatic breast cancer 
patients to 1st, 2nd, and 3rd–line treatments were derived from the Market Research 
Report [2007^2008, 575 breast cancer patients]. The two non-reimbursed agents were 
excluded from the cost estimation. RESULTS: Among the single agents, the cost per 
month of taxanes class based regimen (KRW 1,013,600^2,173,148) is higher than 
anthracyclines class (KRW 120,497 ^ 354,950). The most frequent 1st line treatment, 
namely, docetaxel-based or paclitaxel-based combination chemotherapy was more 
than KRW 2,000,000 per month. The monthly cost of ﬁrst-line agents with trastu-
zumab for HER2-positive disease was from KRW 2,620,030 to 5,085,866. The 
weighted monthly cost of 1st, 2nd, and 3rd line treatment was KRW 1,562,312, 
1,226,304, and 1,322,615, respectively. CONCLUSIONS: The treatment costs of the 
metastaic breast cancer are substantial and vary by regimen in Korea.
